Boehringer Ingelheim and Kyowa Kirin Co., Ltd. have announced a licensing agreement under which Boehringer Ingelheim will develop a potential first-in-class small molecule therapy for autoimmune diseases discovered by Kyowa Kirin.
The agreement grants Boehringer Ingelheim exclusive worldwide rights to the preclinical program. Under the terms, Kyowa Kirin could receive up to €640 million in payments, including an upfront fee, as well as success-based development, regulatory, and commercial milestones, plus royalties on potential sales.
Autoimmune diseases affect around one in ten people worldwide, representing a significant and growing healthcare burden. Despite ongoing advances in treatment, there remains a pressing need for more effective and durable therapies.
Boehringer Ingelheim, recognized for its leadership in autoimmune disease research, continues to pursue novel therapeutic approaches that target underlying disease mechanisms, aiming to deliver highly specific and long-lasting treatments.
“Our commitment to delivering life-changing therapies for patients with autoimmune diseases is unwavering. We are pleased to add a potential first-in-class program to our growing pipeline,” said Carine Boustany, U.S. Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim. “This agreement constitutes an important step toward delivering breakthrough treatments for patients.”
“This compound, discovered through Kyowa Kirin’s deep expertise in innovative technology and disease biology, holds tremendous potential,” said Takeyoshi Yamashita, Ph.D., Executive Vice President and Chief Medical Officer of Kyowa Kirin. “Leveraging Boehringer Ingelheim’s renowned expertise in inflammatory diseases, we are confident that this innovation will be developed efficiently and delivered to the patients who need it most.”
Boehringer Ingelheim is a global biopharmaceutical company active in both human and animal health. As one of the industry’s leading investors in research and development, it focuses on innovative therapies that address high unmet medical needs and aim to improve and extend lives.
Kyowa Kirin Co., Ltd., headquartered in Japan, is a global specialty pharmaceutical company with over 70 years of experience in drug discovery and biotechnology innovation. The company is advancing a pipeline that includes next-generation antibodies, cell and gene therapies, and treatments targeting bone and mineral disorders, intractable hematological and oncological diseases, and rare diseases.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!